Table 1.
Drug name | Immune checkpoint target |
---|---|
Ipilimumab | CTLA-4 |
Tremelimumab | CTLA-4 |
Pembrolizumab | PD-1 |
Nivolumab | PD-1 |
Avelumab | PD-L1 |
Durvalumab | PD-L1 |
Atezolizumab | PD-L1 |
CTLA-4 cytotoxic T lymphocyte-associated antigen 4, PD-1 programmed cell death 1, PD-L1 programmed cell death ligand 1